The FDA posted online 510(k) approval for Sonoma Pharmaceuticals (SNOA)’ Microdacyn Hydrogel, which is intended for use of acute and chronic wounds, ulcers, cuts, abrasions and burns healing.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on SNOA:
- Sonoma Pharmaceuticals reports Q2 (59c) vs ($5.75) last year
- Sonoma Pharmaceuticals expands partnership with healthcare distributor
- Sonoma Pharmaceuticals regains compliance with Nasdaq requirement
- Sonoma receives FDA clearance for expanded indications for Microcyn solution
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
